COLUMBIA, Md.--()--Medifocus, Inc. (OTC:MDFZF.PK and TSXV:MFS) is pleased to announce that it has recently received notice of allowances for two additional international patents to expand its extensive Intellectual Properties (IP) portfolio in addition to the patents Medifocus has exclusively licensed from the Massachusetts Institute of Technology (MIT). The core MIT patents allows the Company to develop tumor-targeted focused heat treatment systems using the adaptive phased array (APA) radar technique which was developed at MIT by Dr. Alan J. Fenn as part of the Strategic Defense Initiative.
“Monopole Phased Array Thermotherapy for Deep Tumor Therapy”
The first of the recently allowed patents is “Thermotherapy Method for Treatment and Prevention of Cancer and Breast Cancer in Male and Female Patients” in Japan. This patent has already been granted by the United States Patent and Trademark Office (USPTO). This patent and several other Company patents forms the basis of the Company’s Clinical Breast Cancer Treatment System, which has already been developed and has been approved by both the United States Food and Drug Administration (FDA), and Health Canada to allow Medifocus to initiate its Phase III Pivotal Clinical Trial both in the USA and Canada. Successful completion of the Phase III trial will lead to commercial approval of the product.
The second recently allowed patent is: “Monopole Phased Array Thermotherapy for Deep Tumor Therapy” which was allowed by the European Patent Office (EPO) and which has already been granted by the USPTO. This patent will allow the company to develop additional focused heat treatment systems for Deep Seated Tumors for Lung, Liver, Ovarian, Prostate, and other tumors.
The allowances of these two patents are significant additions to Medifocus’ extensive IP portfolio to commercially expand on a global basis.
About Medifocus, Inc.
Medifocus owns a patented APA microwave focusing technology platform which can precisely target and concentrate microwave energy to destroy cancer tumors without damaging healthy tissue when used alone or in conjunction with chemotherapy or radiation. The ability to target tumors with a precision controlled dose of heat can be used to destroy tumors at higher temperatures, to treat tumors in combination with chemotherapy and/or radiation at moderate temperatures for increased effectiveness over those treatments alone, and to activate temperature sensitive drugs for tumor targeted localized drug delivery. Medifocus has completed the development of a dedicated commercial cancer treatment system for the treatment of breast cancer and is actively pursuing development of additional systems for other cancers.
Forward-Looking Statements and Information:
This news release contains forward-looking statements, which may not be based on historical facts. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.